Pfizer in advanced talks to buy Global Blood Therapeutics for $5 billion - WSJ
Reuters
Published Aug 05, 2022 11:44AM ET
Updated Aug 05, 2022 12:55PM ET
(Reuters) -Pfizer Inc is in advanced talks to buy drugmaker Global Blood Therapeutics (NASDAQ:GBT) for about $5 billion, the Wall Street Journal reported on Friday, citing people familiar with the matter.
Pfizer (NYSE:PFE) is aiming to seal a deal in the coming days, but other suitors are still in the mix, the report said.
Shares of Global Blood, which makes a blood disorder drug called Oxbryta, soared 44% in afternoon trade to a two-year high. The company had a market capitalization of $3.12 billion, as of Thursday's closing price.
Pfizer declined to comment on the report, while a Global Blood spokesperson said it does not "comment on market rumors or speculation".
New York-based Pfizer, flush with cash from its COVID-19 vaccine, is on the lookout for acquisitions that could bring in billions in annual sales by the end of the decade.
Its $11.6 billion deal for migraine drug maker Biohaven Pharmaceutical Holding in May was the latest in a string of acquisitions including Trillium Therapeutics (NASDAQ:TRIL) and Arena Pharmaceuticals over recent years.
Global Blood's Oxbryta was approved in the United States for the treatment of sickle cell disease among patients 12 years and older in 2019. In December, the oral drug received approval for the treatment of the condition in younger patients as well.
Sales of the drug rose more than 50% to $194.7 million in 2021.
Biotech dealmaking activity has picked up again in recent months after a bleak start to the year, when a dearth of major acquisitions and clinical-stage drug failures dampened investor sentiment and squeezed funding.
On Thursday, Amgen Inc (NASDAQ:AMGN) agreed to buy drugmaker ChemoCentryx (NASDAQ:CCXI) Inc for $3.7 billion to gain access to a potential blockbuster treatment for inflammatory disorders.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.